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Abstract: Clinical manifestations and treatment on dengue hemorrhagic fever
(DHF) were summarized based on 13 years experience of the first author at the
Pediatric Department, Nakorn Phanom Provincial Hospital, Thailand. DHF is an
acute febrile disease, characterized by hemoconcentration, thrombocytopenia, and
coagulopathy. The underlying mechanism of increased vascular permeability,
leads to hemoconcentration, hypovolemic shock, metabolic abnormalities, then
disseminated intravascular coagulation (DIC), if not properly treated. Direct cause
of death in DHF is either circulatory failure or massive hemorrhage. Therefore,
DHF case management should be directed to correct determination of the stage
and grade of the disease, and prescribe proper recipes, such as intravenous infu-
sion and blood transfusion.
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INTRO DUCTION
Den即e virus infection has been prevailing over the world tropics. In the southeast
Asia including Thailand, the appearance of severe clinical manifestation of den即e hemor-
rhagic fever (DHF)!den即e shock syndrome (DSS) has posed serious problems for medical
personnels (Hammon et al.t 1960; Halstead, 1966; World Health Organization, 1966). Besides,
increasing number of patients and enlarging epidemic areas in recent years have made
den即e virus infection as a major health problem in the tropical areas (Halstead, 1992),
Den即e viruses with 4 different serot叩es (Dl, D2, D3, & D4) belong to the genus
flavivirus, family Flaviviridae (Westaway et al, 1985; Wengler, 1991), and are transmitted by
bite of mosquitoes. The principal vector species is Aedes aegypti which breeds in man-made
containers in and around human dwellings. The epidemic season corresponds rainy season
when sufficient precipitation creates abundant mosquito breedi喝sites and high humidity pro-
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vides favorable condition for the activity of vector mosquitoes. In Thailand, the first outbre止
of DHF occurred in Bangkok Metropolitan Area, which was followed by spread into rural
areas. presently, all Provinces in Thailand are endemoepidemic, especially in Northeast and
central Part of Thailand. The epidemiological characteristics of dengue in Nakorn Phanom
province were described in an accompanying paper (Nimnakorn et al, 1994).
In spite of a number of descriptions on the epidemiology and virology of dengue,
reports on clinical manifestations and treatment of DHF are relatively limited (Halstead et al.}
1964; Nimmannitya et al, 1969; 1987; World Health Organization, 1986; Nimmannitya, 1987,
1993a; b). In this communication, the authors intend to summarize the clinical manifestations
and treatment of DHF based on the 13 years experience of the first author at the Pediatnc
Department, Nakorn Phanom Provincial Hospital, Thailand.
MATERIALS AND METHODS
Materials and data: These were summarized from clinical records at the Pediatnc Depart-
ment, Nakorn Phanom Provincial Hospital.
RESULTS AND DISCUSSIONS
Clinical manifestation of typical DHF
●
Age distribution of the hospitalized DHF cases in Nakorn Phanom Provincial Hospital
during 1987 to 1992 is shown in Table 1. Similar to other dengue epidemic areas in
Thailand, most of the cases were children under 14 years old.
clinical characteristics of DHF are: (1) acute high fever, (2) hemorrhagic diathesis, (3)
hepatomegaly with tenderness, and (4) circulatory disturbances and shock.
The course of the disease can be classified into 3 stages (Fig. 1). Stage 1 (Febrile
stage) lasts for 2-7 days, with average of 4 days, and seldom persists more than 14 days.
Among more than 10,000 cases observed at紅e Pediatric Department, Nakorn Phanom Pro―
vincial Hospital, only a single case was recorded for each of the febrile period of 2 days, 7
●
days and 10 days,
Table l･ Age distribution of hospitalized DHF Cases in Nakorn Phanom

















Days of the disease
Fig. 1. Stages in DHF
(1) Fever stage, (2) shock stage, (3) recovery stage. Ordinate:
body temperature in ℃, abscissa: days of the disease
Stage 2 (shock stage) does not usually last more than 48 hours, but rare cases血ow
more than 72 hr血ock period.
Stage 3 (recovery stage) is also the stage of complications
Pa紅op血ysiology and pa紅ogenesis of DHF
As described by several literatures (Halstead et al, 1964; Nimmannitya et al, 1969;
1987; World Health Organization, 1986; Nimmannitya, 1987, 1993a), clinical manifestations
of DHF are caused by (1) increased vascular permeability, (2) abnormal hemostasis, and (3)
bleeding tendency, which could be accompanied by thrombocytopenia, coagulopathy, and
disseminated intravascular coa即Iation (DIG). Increased vascular permeability lead to ex-
travasation of plasma, which can be manifested in pleural ef山sion (Fig. 2) or ascitic fluid
(Fig. 3), and resulting in hypovolemic shock. Clinical classification of DHF into 4 grades has
been well-documented (World Health Organization, 1986), therefore will not be reiterated
here.
Major manifestations in DHF
Fever is a major manifestation in DHF and persists 2-4 days in 70% of the cases
while the remaining 30% shows 5-7 days of fever. Exceptional cases with shorter or longer
febrile period have been described above.
Next major manifestation of DHF is hemorrhagic tendency. Its mildest form can be
demonstrated by po由tive Tourniquet test, and its positive rate along the day of the disease is
shown in Table 2. More pronounced hemorrhagic tendency will be seen as spontaneous
bleeding such as, petechiae, epistaxis,即m bleeding, ecchymosis, melena, and hematemesis,
the frequency of which is shown in Table 3. The petechiae can be observed in anterior chest



































Fig. 2. Chest X ray film of DHF cases with pleural effusion, Nakorn Phanom Provincial
Hospitral, Thailand
panel A: bilateral plueral effusion with cardiomegaly; Panel B: right unilateral
pleural effusion,
Fi.g S. A DHF patient with distended abdomen
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Table 2. Frequency of positive Tourni-
quet test found in DHF patients












Remarks: in shock s也ge, the test turns into
negative, then returns to positive in recovery
stage
Table 3. Spontaneous bleeding manifestations










mities. Hepatomegaly is another major clinical manifestation in DHF. Although negative on
●　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　●
the lst day of the disease except in the patients less than 1 year old, hepatomegaly can be
observed with increasing rate along the days of the disease (20% on the 2nd day, 90% on
the 3rd day, and lOO% on the 4th day, respectively). Adult patients o鮎n shows hepatomega-
1y on the 4th day of the disease.
Nonspecific symptoms in DHF
Table 4 shows nonspecific symptoms seen in DHF cases and their frequencies. It
should be pointed out that significant proportion of DHF cases show injected pharynx or com-
plain abdominal pain and headache, which could lead to mis―diagnosis of respiratory or
gastroentenc infections,
Diagnosis o皿DHF
Diagnosis on DHF depends on above-mentioned clinical manifestations as well as
laboratory findings. Demonstration of thrombocytopenia (< 100,000!c皿3) and hemoconcentra-
tion (more than 20% increase in the hematocrit) are diagnostic. These clinical and laboratory
findings should be supported by the virological confirmation, the principle of which consists
●
of serological test and virus isolation. The former was routinely carried out by the hem昭一
glutmation｢inhibition (HI) test, but was improved by the introduction of lgM-ELISA.
Virus isolation requires several days long and expertise, however, recent introduction of PCR
detection of viral genome made the procedure much shorter and simpler.
98
Table 4. Nonspecific symptoms observed in DHF patients
Symptoms Frequency Remarks
Injected pharynx
































Under 1 years old
ln young patients
2 cases Less than 6 months
Case management of DHF
Principle of the case management for DHF depends on the identification of the stage
and the grade of the disease,
The outpatients in the lst stage of fever should be given (1) oral rehydration (ORS) to
correct dehydration, (2) anticonvulsive dri喝s in the case of convulsions, (3) antipyretic
(preferably acetaminophen), and (4) 5% dextrose: physiological saline (1:1 mixture) if
necessary.
The DHF grade I and I patients in hemorrhagic and血ock stage in the outpatients
should be given symptomatic recipes such as ORS and should be followed up every day. In
the case of inpatients, intravenous infusion血ould be given, with following recipes; isotonic
●　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　●　　　　　　　　　　　　　　　　　　●
solutions (5% dextrose-physiological saline 1:1 mixture, or 5% Ringer-lactose), 7- 10 ml/kg
body weigh仙r. Vital signs血ould be examined every hour and hematocrit shoi且Id be examin―
ed every 4 hr to monitor hemoconcentration and impeding shock.
The grade in and IV inpatients with shock should be given intravenous ir血sion depen-
■
ding on the clinical manifestations. The shock management血ould be aimed to correct major
pathophysiological changes. It should be reminded that DSS is hypovolemic shock due to
massive leakage of plasma which continues for 24-48 hours in most of the cases. Also, it is
important to remember that hyponatremia and metabolic acidosis are common, particularly in
severe cases. There is a high potentiality to develop DIC which can lead to fatal massive
hemorrhage, because stagnant acidemic blood can precipitate DIG.
Along the above-mentioned principles, the first choice in the DHF treatment is the
●
rapid replacement of existing plasma loss. This can be achieved by intravenous infusion with
5% dextrose-physiological saline, dextrose-Ringer-lactate, 10 -20ml/kg body weight/hr.
In the case of profound shock, colloidal solution (dextran 40, or plasma) should be given at
doses of 20ml!家body weight･ The continuation of the replacement therapy depends on the
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hematocrit values; reducing the speed from 20 to 15, 10, and 5mykg/hr when hematocrit is
decreasing; or other way around when hematocrit血ows increasing trend. It is important to
provide minimum essential intravenous infusion to maintain adequate tissue perfusion. The
case which sho- worsened vital signs in spite of decreasing hematocrit should be suspected
of massive (internal) hemorrhage and transfusion with fresh whole blood should be indicated.
Correction of electrolytes and acid-base imbalance is also important. Particular atten-
tion sho山d be paid to correct hyponatremia, water intoxication which can lead to convulsion,
metabolic acidosis, which predispose DIG.
Blood transfusion (fresh whole blood 10-20ml/kg) should be prescribed for the cases
with significant bleeding, particularly internal bleeding. Such cases show decreased
hematocrit, reduced blood pressure and weak pulse. For very severe cases, fresh frozen
plasma, concentrated platelet, or c叩^precipitate (Factor w) should be given,
Other supportive cares, oxygen therapy and calm down therapy with chloral hydrate
(15 -50mg/kg/dose; maximum lgm) should be prescribed when necessary.
Mo皿itori皿g patie皿ts'co皿ditio皿S
This should be carried out by frequent recording vital signs (blood pressure and pulse
every 30 mm during shock, and every hr after the shock). Hematocrit should be measured
everyト3 hr for the lst 6 hrs, then every 4-6 hrs. Fluid balance sheet with type and rate
of intravenous in血sion intake and urine output should be prepared.
In the case of prolonged shock, central venous pressure (CVP)血ould be measured.
When CVP is greater than 15mm H20, Furosamide li腸/kg should be given intravenously. The
patients showing pulmonary edema should be treated with blood letting.
Treatment in血e recovery如age
Following complications can occur in this stage: (1) overloaded intravenous infusion can
cause pulmonary edema, which should be treated by Furosamide or blood letting; (2)
pneumonia particularly in the case of massive pleural effusion, (3) septicemia due斗′　血ng-
ed shock, urinary catheter, or central venous line, (4) intracerebral hemorrhage as a result of
DIG, (5) hyponatremia, and (6)血ypocalcemia,
Unusual manifestatio皿of DHF
Followings unusual manifestations can be seen in DHF:
(1) In the infants less than 1 year old
The case血owed high fever, convulsion, diarrhea, hepatomegaly on the lst day, but
plasma leakage was not remarkable, petechiae at forearms and legs, bleeding is rare but once
occurred could be massive and fatal.
(2) Children between 1.5｢3 years old
Approximately l哨of the cases show pneumonia until the 3rd or 4th day of the fever
before DHF symptoms can be detectable.
(3) Rare case with viral encephalitic syndrome
High fever is accompanied by severe headache, vomiting, and stiff neck. Cerebrospinal
fluid shows characteristics of viral encephalitis. Such symptoms lasts until the 3rd to 4th day
of the fever before DHF symptoms were observed. In relation to this unusual manifestation,
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den即e encephalopathy was documented with elevated serum transaminases and symptoms
similar to Reye's syndrome and hepatic encephalopathy. The best recipes is early exchange
transfusion.
(4) In adult
Tourniquet test remains negative during the early days, then turns into positive on the
3rd or 4th day. Hepatom曙aly is always positive on the 4th day of the fever. Plasma leakage
is not remarkable. Bleeding is rare, but once occurs may be massive and fatal.
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